日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

KEYNOTE-001 研究中接受帕博利珠单抗治疗的晚期黑色素瘤患者的五年生存结果

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdz011
Hamid, O; Robert, C; Daud, A; Hodi, F S; Hwu, W J; Kefford, R; Wolchok, J D; Hersey, P; Joseph, R; Weber, J S; Dronca, R; Mitchell, T C; Patnaik, A; Zarour, H M; Joshua, A M; Zhao, Q; Jensen, E; Ahsan, S; Ibrahim, N; Ribas, A
黑色素瘤
发表日期：2019
文献求助 收藏

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

帕博利珠单抗作为PD-L1阳性晚期非小细胞肺癌患者的一线治疗：一项I期试验

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdx008
Hui, R; Garon, E B; Goldman, J W; Leighl, N B; Hellmann, M D; Patnaik, A; Gandhi, L; Eder, J P; Ahn, M-J; Horn, L; Felip, E; Carcereny, E; Rangwala, R; Lubiniecki, G M; Zhang, J; Emancipator, K; Roach, C; Rizvi, N A
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
发表日期：2017
文献求助 收藏

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

一项针对晚期实体瘤患者的口服泛FGFR抑制剂ARQ 087的I期研究

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2017.330
Papadopoulos, K P; El-Rayes, B F; Tolcher, A W; Patnaik, A; Rasco, D W; Harvey, R D; LoRusso, P M; Sachdev, J C; Abbadessa, G; Savage, R E; Hall, T; Schwartz, B; Wang, Y; Kazakin, J; Shaib, W L
发表日期：2017
文献求助 收藏

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

copanlisib (BAY 80-6946) 是一种静脉注射的泛 I 类磷脂酰肌醇 3-激酶抑制剂，用于治疗晚期实体瘤和非霍奇金淋巴瘤患者，这是首次人体 I 期研究。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw282
Patnaik, A; Appleman, L J; Tolcher, A W; Papadopoulos, K P; Beeram, M; Rasco, D W; Weiss, G J; Sachdev, J C; Chadha, M; Fulk, M; Ejadi, S; Mountz, J M; Lotze, M T; Toledo, F G S; Chu, E; Jeffers, M; Peña, C; Xia, C; Reif, S; Genvresse, I; Ramanathan, R K
信号转导
淋巴瘤
发表日期：2016
文献求助 收藏

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

ficlatuzumab 单药治疗或与厄洛替尼联合治疗难治性晚期实体瘤和多发性骨髓瘤的 I 期临床试验

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2014.290
Patnaik A, Weiss G J, Papadopoulos K P, Hofmeister C C, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo F C, Cotreau M M, Ramanathan R K
肿瘤
骨髓瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

Brucella endocarditis - a series of five case reports

布鲁氏菌性心内膜炎——五例病例报告

期刊:Indian Heart Journal
影响因子:1.8
doi:10.1016/j.ihj.2012.12.017
Raju, I Tammi; Solanki, Rachana; Patnaik, A N; Barik, R C; Kumari, N R; Gulati, A S
发表日期：2013
文献求助 收藏

A perspective on the PCPNDT Act

对《产前诊断技术（性别选择）法》的看法

期刊:Indian Journal of Radiology and Imaging
影响因子:1
doi:10.4103/0971-3026.101116
Patnaik, A Murali Mohan; Kejriwal, Gouri Shankar
发表日期：2012
文献求助 收藏

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

一项针对晚期实体瘤患者的lexatumumab (HGS-ETR2) 每2周给药一次的I期和药代动力学研究

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdp292
Wakelee, H A; Patnaik, A; Sikic, B I; Mita, M; Fox, N L; Miceli, R; Ullrich, S J; Fisher, G A; Tolcher, A W
发表日期：2010
文献求助 收藏